| John Edward Reardon, MD | |
|
4145 Carmichael Rd, Montgomery, AL 36106-2803 | |
| (334) 273-7000 | |
| (334) 273-2228 |
| Full Name | John Edward Reardon |
|---|---|
| Gender | Male |
| Speciality | Hematology/oncology |
| Experience | 22 Years |
| Location | 4145 Carmichael Rd, Montgomery, Alabama |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1679786354 | NPI | - | NPPES |
| 111323 | Medicaid | AL |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RH0003X | Internal Medicine - Hematology & Oncology | 25742 (Alabama) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Baptist Medical Center South | Montgomery, AL | Hospital |
| Baptist Medical Center East | Montgomery, AL | Hospital |
| Jackson Hospital & Clinic Inc | Montgomery, AL | Hospital |
| Prattville Baptist Hospital | Prattville, AL | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Health Care Authority For Baptist Health, An Affiliate Of Uabhs | 8426076670 | 179 |
News Archive
Regulus Therapeutics Inc. today announced the establishment of a new collaboration with GlaxoSmithKline (GSK) to develop and commercialize microRNA therapeutics targeting microRNA-122 in all fields with Hepatitis C Viral infection (HCV) as the lead indication. Under the terms of the new collaboration, Regulus will receive additional upfront and early-stage milestone payments with the potential to earn more than $150 million in miR-122-related combined payments, and tiered royalties up to double digits on worldwide sales of products.
Twenty years after the first identification of the BRCA1 gene, the University of Pennsylvania's Basser Research Center for BRCA will honor the geneticist credited with its founding with the second annual Basser Global Prize.
SensAble Technologies, Inc®, a leading provider of 3D modeling software, haptic devices and dental restoration design and fabrication solutions, announced that it has received an $8 million investment to propel sales, marketing and engineering efforts for its digital dentistry product line. Existing investor HLM Venture Partners led the round and was joined by North Bridge Venture Partners, both of whom are headquartered in the Boston area, and have extensive expertise with medical device company funding.
The anti-obesity medication rimonabant showed mixed results in slowing progression of coronary artery disease in patients with abdominal obesity and pre-existing coronary disease, according to a new study in the April 2 issue of JAMA.
Ann Williams, a National Institute of Health-supported postdoctoral fellow at Case Western Reserve University, understands what it means to live with diabetes.
› Verified 6 days ago
| Entity Name | Health Care Authority For Baptist Health, An Affiliate Of Uabhs |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1982653390 PECOS PAC ID: 8426076670 Enrollment ID: O20060220000538 |
News Archive
Regulus Therapeutics Inc. today announced the establishment of a new collaboration with GlaxoSmithKline (GSK) to develop and commercialize microRNA therapeutics targeting microRNA-122 in all fields with Hepatitis C Viral infection (HCV) as the lead indication. Under the terms of the new collaboration, Regulus will receive additional upfront and early-stage milestone payments with the potential to earn more than $150 million in miR-122-related combined payments, and tiered royalties up to double digits on worldwide sales of products.
Twenty years after the first identification of the BRCA1 gene, the University of Pennsylvania's Basser Research Center for BRCA will honor the geneticist credited with its founding with the second annual Basser Global Prize.
SensAble Technologies, Inc®, a leading provider of 3D modeling software, haptic devices and dental restoration design and fabrication solutions, announced that it has received an $8 million investment to propel sales, marketing and engineering efforts for its digital dentistry product line. Existing investor HLM Venture Partners led the round and was joined by North Bridge Venture Partners, both of whom are headquartered in the Boston area, and have extensive expertise with medical device company funding.
The anti-obesity medication rimonabant showed mixed results in slowing progression of coronary artery disease in patients with abdominal obesity and pre-existing coronary disease, according to a new study in the April 2 issue of JAMA.
Ann Williams, a National Institute of Health-supported postdoctoral fellow at Case Western Reserve University, understands what it means to live with diabetes.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| John Edward Reardon, MD 4145 Carmichael Rd, Montgomery, AL 36106-2803 Ph: (334) 273-7000 | John Edward Reardon, MD 4145 Carmichael Rd, Montgomery, AL 36106-2803 Ph: (334) 273-7000 |
News Archive
Regulus Therapeutics Inc. today announced the establishment of a new collaboration with GlaxoSmithKline (GSK) to develop and commercialize microRNA therapeutics targeting microRNA-122 in all fields with Hepatitis C Viral infection (HCV) as the lead indication. Under the terms of the new collaboration, Regulus will receive additional upfront and early-stage milestone payments with the potential to earn more than $150 million in miR-122-related combined payments, and tiered royalties up to double digits on worldwide sales of products.
Twenty years after the first identification of the BRCA1 gene, the University of Pennsylvania's Basser Research Center for BRCA will honor the geneticist credited with its founding with the second annual Basser Global Prize.
SensAble Technologies, Inc®, a leading provider of 3D modeling software, haptic devices and dental restoration design and fabrication solutions, announced that it has received an $8 million investment to propel sales, marketing and engineering efforts for its digital dentistry product line. Existing investor HLM Venture Partners led the round and was joined by North Bridge Venture Partners, both of whom are headquartered in the Boston area, and have extensive expertise with medical device company funding.
The anti-obesity medication rimonabant showed mixed results in slowing progression of coronary artery disease in patients with abdominal obesity and pre-existing coronary disease, according to a new study in the April 2 issue of JAMA.
Ann Williams, a National Institute of Health-supported postdoctoral fellow at Case Western Reserve University, understands what it means to live with diabetes.
› Verified 6 days ago
Dr. Jack Parmer Evans, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 1301 E South Blvd, Montgomery, AL 36116 Phone: 334-281-8008 Fax: 334-281-0090 | |
Dr. Shyam Padmanabhan, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 2055 E South Blvd Ste 403, Montgomery, AL 36116 Phone: 334-613-0807 | |
Dr. April A Truett, M.D. Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 215 Perry Hill Rd, Montgomery, AL 36109 Phone: 334-272-4670 | |
Vivian G Hamlett, MD Hematology & Oncology Medicare: Medicare Enrolled Practice Location: 440 Taylor Rd, Suite 3200, Montgomery, AL 36117 Phone: 334-213-6281 Fax: 334-213-6288 | |
Monjurul Islam, M.D. Hematology & Oncology Medicare: Not Enrolled in Medicare Practice Location: 215 Perry Hill Rd, Montgomery, AL 36109 Phone: 334-272-4670 | |
Jacquelin Ratunil Chua, MD Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 1722 Pine St, Montgomery, AL 36106 Phone: 334-293-8000 | |
Dr. Julie Elizabeth Orender, M.D. Hematology & Oncology Medicare: Accepting Medicare Assignments Practice Location: 3817 Colline Dr, Montgomery, AL 36106 Phone: 334-224-2813 Fax: 334-356-0890 |